Tag Archives: CERU

Cerulean Pharma Inc. (CERU)

Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

News about CERU

Cerus Co. (CERS) CFO Kevin Dennis Green Sells 2,783 Shares
Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of the business’s stock in a transaction that occurred on Wednesday, October 10th. The shares were sold at an average price of $6.09, for a total transaction of $16,948.47. Follow...Read More>>>

BidaskClub Lowers Cerus (CERS) to Sell
BidaskClub downgraded shares of Cerus (NASDAQ:CERS) from a hold rating to a sell rating in a research note released on Thursday. Several other brokerages also recently weighed in on CERS. Zacks Investment Research upgraded Cerus from a hold rating to...Read More>>>

Cerus (CERS) and Neovasc (NVCN) Head-To-Head Analysis
Cerus (NASDAQ:CERS) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profit...Read More>>>

Acerus Pharmaceuticals Co. (ASP) Director Stephen Robert Gregory Acquires 42,000 Shares of Stock
Acerus Pharmaceuticals Co. (TSE:ASP) Director Stephen Robert Gregory purchased 42,000 shares of the stock in a transaction that occurred on Tuesday, August 21st. The shares were acquired at an average cost of C$0.24 per share, with a total value of C...Read More>>>

Dare Bioscience (DARE) Receives Media Sentiment Score of 0.17
Media stories about Dare Bioscience (NASDAQ:DARE) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time...Read More>>>